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use#LAAFrom  quantitative  trait  locus  mapping  and  linkage 
analysis  to  genome-wide  association  studies  (GWASs), 
genetic markers have been used to locate causal genes 
underlying Mendelian and complex traits with impressive 
success: the molecular basis for nearly 3,000 Mendelian 
disorders is known [1] and over 4,500 single nucleotide 
polymorphisms  (SNPs)  have  been  associated  with  a 
variety of human traits and complex diseases [2]. These 
studies rely on linkage with the disease-causing variant 
and, by their very nature, indirect genetic marker studies 
have  limitations.  The  causal  variant  or  gene  remains 
unknown for the majority of the 4,500 SNPs associated 
with  complex  disease  and  for  over  3,500  Mendelian 
disorders. New sequencing-based studies have emerged 
and are poised to change genetic mapping fundamentally 
by enabling the direct identification of causal sequence 
variants in a single experiment. We will no longer have to 
rely on linkage with the disease-causing variant; instead, 
by obtaining full sequence data for all genes we can now 
directly  test  for  association  with  disease.  As  we  have 
learned in the past few years, however, there is a great 
deal of human genetic variation [3] and finding the causal 
variant among thousands of candidates can be difficult.
Here  we  review  the  computational  and  statistical 
approaches that have emerged for managing these data in 
this rapidly exploding field. First, we briefly review the 
process  for  identifying  variants  in  next-generation 
sequencing (NGS) studies and then discuss strategies for 
identifying  the  causal  variant  in  Mendelian  disorders 
among the total number of variants identified. We also 
discuss  strategies  for  identifying  the  causal  gene(s)  in 
complex diseases among all genes in the genome, before 
outlining  some  challenges  facing  current  exome 
sequencing studies.
Variant discovery in exome sequencing projects
NGS  methods  have  been  developed  that  harness 
massively parallel DNA sequencing [4] and enable large-
scale sequencing projects that have applications ranging 
from cataloging genetic diversity on a population level [3] 
to  identifying  a  disease-causing  variant  in  a  single 
individual,  which  might  lead  to  directed  therapy  [5]. 
Most large-scale medical sequencing projects so far have 
focused on the protein-coding region of the genome (the 
‘exome’).  This  has  been  driven  in  part  by  cost  (whole 
genome sequencing is still relatively expensive for large 
sample sizes), biology (most known examples of disease-
causing variants alter the protein sequence), and practical 
considerations  (there  is  currently  little  consensus  on 
interpreting non-coding genetic variation).
Various  methods  have  been  developed  to  select  a 
subset  of  the  genome  for  sequencing,  but  only  solid-
phase  hybridization  [6]  and  liquid-phase  hybridization 
[7]  have  been  commercially  applied  for  selecting  the 
entire  human  exome  as  the  target  for  sequencing.   
After target enrichment, sequencing is performed using 
various  NGS  technologies,  including  reversible 
terminator  reactions,  sequencing  by  ligation, 
pyrosequencing  and  real-time  sequencing  [8].  These 
generate millions of short sequence copies, or reads, tiled 
across the portions of the reference genome that were 
targeted.  Although  numerous  algorithms  have  been 
developed to align NGS reads to the reference genome 
(Bowtie, Short Oligonucleotide Analysis Package (SOAP) 
and Blat-like Fast Accurate Search Tool (BFAST), among 
others [9]), most sequencing projects use Mapping and 
Assembly with Qualities (MAQ) [10] or the Burroughs-
Wheeler Aligner (BWA) [11] because of computational 
efficiency and multi-platform compatibility. The resulting 
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from the human reference sequence and are identified as 
SNPs.
As with alignment tools, many algorithms have been 
developed  to  identify  a  high-quality  set  of  variants  in 
NGS projects. Most current SNP discovery tools rely on 
the calculation of genotype likelihoods at each position 
[10],  defined  as  the  probability  of  observing  the   
given  sequencing  data  (base  calls  and  base  quality   
scores)  at  that  position  given  a  set  of  underlying 
genotypes. Bayesian posterior probabilities can then be 
calculated for each potential genotype [12]. Two popular 
tools  for  SNP  discovery  in  NGS  data  that  are  easily 
incorporated  into  data-processing  pipelines  are 
SAMtools  [13]  and  the  Genome  Analysis  Toolkit 
UnifiedGenotyper  [14,15].  Other  tools  have  been 
developed  to  exploit  aspects  of  specific  types  of  NGS 
technologies  (optimizing  base  quality  estimates  from 
pyrosequences,  for  example)  [16-18]  or  low-coverage 
sequencing data [18,19].
By applying the appropriate tool one can identify a set 
of positions in the sequencing data that are different from 
the  reference  sequence  along  with  an  indication  of 
genotype quality. Typically 15,000 to 20,000 variants are 
discovered per exome, with the variation in this number 
occurring from different exome target definitions [20-23] 
(a target set with fewer genes or exons would be expected 
to have fewer total variants) and ancestry (individuals of 
African  ancestry  have  more  variants  per  exome  than 
individuals  of  European  ancestry  [3],  for  example).  By 
contrast, about 3 million SNPs per genome are discovered 
using  whole-genome  sequencing  [24]  because  of  the 
larger  sequencing  target  (whole  genome  sequencing 
targets about 3 Gb, whereas the typical exome target is 
about 33 Mb). To facilitate the processing and sharing of 
these large datasets, the Variant Call Format (VCF) text 
file  format  [3]  is  emerging  as  the  accepted  format  for 
reporting sequence variation from NGS projects, and the 
SAM/BAM file format is routinely being used for storing 
and sharing raw NGS data [13].
Challenges for variant discovery in exome sequencing 
projects
Because even a single base-pair change can be associated 
with  disease,  SNP  discovery  algorithms  must  robustly 
distinguish true variation from sequencing errors. This 
challenge is magnified in exome sequencing projects, in 
which discovering rare variants is often the goal. NGS 
has an inherently higher per-base error rate than Sanger 
sequencing [25] but is generally thought to compensate 
for these errors with much higher coverage (most NGS 
experiments for disease-association generate an average 
of  greater  than  20-  to  30-fold  coverage).  Despite  this 
degree of coverage, however, the higher error rate of NGS 
can  introduce  false-positive  associations  if  cases  and 
controls have differential coverage depths [26]. In large-
scale  sequencing  projects  aimed  at  discovering  rare 
variants  associated  with  complex  disease,  differential 
coverage between cases and controls should be one of the 
quality control metrics (of potentially many); however, a 
standardized quality control approach to NGS data has 
not yet emerged.
Applying exome sequencing to Mendelian 
disorders
Exome sequencing has been successfully used to find the 
causal  variant  in  several  Mendelian  disorders,  such  as 
Miller syndrome [27] (a rare autosomal recessive disorder 
characterized  by  craniofacial  abnormalities),  Kabuki 
syndrome [28] (an autosomal dominant form of mental 
retardation with facial abnormalities), and many others 
[29]. It is emerging as an attractive method for disease-
gene mapping in Mendelian traits when linkage studies 
have been inconclusive or impossible [23] (often owing to 
low numbers of affected individuals) or when looking for 
causal de novo mutations [20,28]. Successful studies have 
typically analyzed fewer than ten individuals and often 
only  affected  individuals  have  been  sequenced.  These 
small studies are underpowered for detecting association 
using  currently  available  association  tests  and  use  a 
different  analytic  approach  for  novel  gene  discovery 
compared  with  methods  developed  for  the  analysis  of 
complex diseases.
Identifying causal variants: filtering
Various  heuristic  filtering  methods  have  been  used  to 
narrow  the  search  for  the  causal  variant  from  about 
20,000 to often a single variant, or to a single gene (with 
several independent variants; Figure 1). In general these 
heuristic filters rely on four main assumptions: (1) the 
causal  variant  will  alter  the  protein  coding  sequence; 
(2) it will be extremely rare (often assumed to be shared 
only by cases in one family); (3) every carrier of a putative 
disease-causing  variant  will  have  the  phenotype 
(complete penetrance); and (4) every individual with the 
disorder will carry the putative disease-causing variant 
(that  is,  complete  detectance,  or  100%  probability  of 
observing a genotype given the phenotype). Functional 
annotation can divide variants into synonymous variants 
(those  that  do  not  change  the  amino  acid  sequence), 
missense  variants  (those  that  introduce  an  amino  acid 
change),  and  loss-of-function  variants  (those  that 
prematurely  truncate  proteins  and  those  disrupting 
protein  splicing).  Approximately  50  to  75%  of  variants 
can be removed from consideration by focusing only on 
nonsynonymous (protein-altering) changes [30,31]. Some 
studies further divide variants into different classes on 
the basis of the predicted effects of the protein alterations 
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[34] or PhyloP [35]). Under the assumption that variants 
responsible for Mendelian disorders will not be present 
in  publicly  available  databases  of  human  genetic 
variation, investigators have removed variants for further 
consideration  if  they  are  found  in  HapMap  [36],  1000 
Genomes Project [3], dbSNP [37], and privately available 
variants from other exome sequencing projects (typically 
shared controls or cases for other phenotypes sequenced 
locally).  Restricting  the  search  to  nonsynonymous 
variants  not  present  in  available  databases  currently 
reduces  the  list  of  putative  causal  variants  to 
approximately 200 to 500 [23,27,38].
Finding causal variants under a recessive model
To further narrow the search, investigators have imposed 
a recessive model of disease when the pedigree suggests 
this  mode  of  inheritance,  requiring  a  putative  causal 
variant  to  be  present  in  a  homozygous  state  for  all 
individuals  (while  absent  in  public  databases),  or  for 
individuals to be compound heterozygotes in the putative 
gene (carrying two separate variants in the same gene), 
which  can  reduce  the  list  to  a  single  variant  or  gene 
[20,22,23].  This  has  been  successfully  performed  in  at 
least  11  studies  of  recessive  disorders  with  various 
numbers of individuals down to as few as one, in which a 
single  individual  with  Perrault  syndrome  (ovarian 
dysgenesis  with  sensorineural  deafness)  was  found  to 
have  two  separate  non-synonymous  variants  in 
HSD17B4, a gene that is involved in peroxisomal fatty 
acid β-oxidation.
These simple filtering techniques may not be sufficient, 
however, and additional approaches might be needed to 
further narrow the search. An example of this was the use 
of an identity by descent analysis in a sequencing study to 
discover  the  cause  of  hyperphosphatemia  mental 
retardation syndrome [39]. After common variants were 
excluded  from  the  list  of  shared  variants  among  three 
affected  individuals,  14  candidate  genes  were  left;  of 
these, however, only two were found in regions of the 
exome that were inferred to be identical by descent. PIGV 
(encoding  phosphatidylinositol  glycan  class  V),  a  gene 
that  is  involved  in  the  synthesis  of  glycosyl-
phosphatidylinositol,  was  identified  as  the  causal  gene 
after  the  final  two  candidate  genes  were  sequenced  in 
additional  families.  Our  guess  is  that  after  the  ‘low-
hanging  fruit’  are  found,  additional  novel  methods 
incorporating techniques from population and statistical 
genetics  will  be  needed  to  identify  causal  genes  in 
sequencing  projects  in  which  the  answer  is  not 
immediately apparent.
Finding causal variants under a dominant model
In contrast to the autosomal recessive model of disease, 
there have been fewer published examples of novel gene 
association  with  autosomal  dominant  disorders  (only 
four have yet been published [29]), perhaps highlighting 
the relative difficulty in finding such causal genes with 
exome  sequencing.  The  general  approach  in  the 
dominant  model  also  relies  on  filtering  a  list  of 
nonsynonymous  variants  to  exclude  those  previously 
identified  in  either  public  databases  or  shared  control 
exomes,  and  it  requires  affected  individuals  to  be 
heterozygous  for  the  same  variant  [31]  or  to  be 
heterozygous for different variants in the same gene [28]. 
As  a  proof  of  principle  for  exome  sequencing  in  gene 
discovery  for  Mendelian  disorders,  the  exomes  of  four 
individuals  with  Freeman-Sheldon  syndrome  (a  rare 
autosomal dominant disorder previously known to arise 
from mutations in myosin heavy chain 3, MYH3) were 
sequenced in one of the first publications detailing exome 
sequencing  of  multiple  individuals  [22].  MYH3  was 
Figure 1. Typical heuristic filtering applied to exome sequencing 
projects aimed at novel gene discovery for Mendelian disorders, 
along with key assumptions at each step. Each individual carries 
approximately 3 million SNPs. Sequential filters shown here can 
be applied to reduce the number of potential disease-associated 
variants.
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variants in all four individuals while being absent from 
dbSNP and other control exomes.
Challenges for exome sequencing for Mendelian disorders
All  exome  sequencing  studies  for  gene  discovery  in 
Mendelian  disorders  have  relied  on  the  assumption  of 
complete  penetrance.  Under  this  assumption,  they 
exclude variants from consideration if present in public 
catalogs  of  human  genetic  variation  or  unpublished 
datasets. As these databases expand, however, disease-
causing variants might appear in one or more publicly 
available  datasets.  The  limitation  of  requiring  absence 
from these datasets is also apparent when one allows for 
a genetic model of incomplete penetrance (that is, if the 
phenotype is present in only some fraction of carriers). In 
the future such a filtering strategy might need to specify a 
minor  allele  frequency  threshold  in  such  datasets  as 
opposed to requiring complete absence. The converse of 
penetrance  (the  probability  of  observing  a  phenotype 
given  a  genotype)  is  detectance  (the  probability  of 
observing a genotype given a phenotype), and almost all 
exome sequencing studies for Mendelian disorders have 
relied  on  a  model  of  complete  detectance.  The  causal 
gene for Kabuki syndrome, however, was found only after 
allowing for incomplete detectance [28], and might not 
have been identified as MLL2 (mixed lineage leukemia 2) 
if  the  discovery  panel  had  not  been  so  enriched  for 
carriers  (90%  of  the  discovery  panel  carried  a  loss-of-
function  variant  in  MLL2  compared  with  60%  of  the 
replication  panel).  In  the  future,  better  tests  will  be 
needed  that  incorporate  incomplete  penetrance  and 
detectance. However, it is clear that integration of gene 
length will be critical, as longer genes will dominate the 
results given the greater numbers of variants due to their 
size.
Applying exome sequencing to complex disease
GWASs have been performed for many complex traits 
and  have  identified  associations  with  thousands  of 
common variants (minor allele frequency typically over 
5%),  each  conferring  a  modest  increase  in  risk  among 
carriers (with odds ratios rarely above 1.3 [40]). These 
‘risk  alleles’  are  typically  not  causal  and  are  associated 
with the phenotype of interest because of linkage with 
the  causal  variant.  Exome  sequencing  studies 
fundamentally  differ  from  GWASs  because,  in  theory, 
they  enable  unbiased  variant  discovery  and  allow  for 
direct association between phenotype and causal variant. 
The driving hypothesis behind complex disease exome-
sequencing  studies,  motivated  by  the  results  of  early 
sequencing studies [41-44], is that multiple rare variants 
in protein-coding genes contribute to the trait of interest. 
Focusing on rare genetic variation is also supported by 
studies  predicting  that  numerous  functional  and 
deleterious  variants  segregate  in  the  population  at 
frequencies (0.5 to 5%) too low to be detected by GWASs 
[45-47]. These rare variants pose an analytical challenge, 
however, because they are present in so few individuals 
that there is low power to detect an association. Although 
we  are  still  awaiting  the  results  of  the  first  exome 
sequencing  studies  for  complex  diseases,  we  review 
(below and in Figure 2 and Additional file 1) the available 
tests for rare variant association, some of which are likely 
to  be  applied  in  ongoing  projects  (such  as  the  Exome 
Sequencing Project from the National Heart Lung and 
Blood Institute [48]).
Single variant tests
The simplest approach to analyzing variants from exome 
sequencing data is to examine each one individually for 
association  with  the  given  phenotype.  For  example, 
dichotomous  traits  (myocardial  infarction,  diabetes, 
schizophrenia, and so on) can be analyzed using the χ2 
test for contingency tables, Fisher’s exact test, Cochran-
Armitage test for trend, or logistic regression [49]. These 
methods test for an enrichment of the ‘risk’ allele in cases 
or controls (if seen more frequently in controls, it would 
be  deemed  a  ‘protective’  allele).  An  example  would  be 
finding a variant present in 3% of cases but only 1% of 
controls. Whether this overrepresentation is statistically 
significant depends on the total number of individuals in 
the study and the required level of statistical stringency. 
Quantitative traits (such as blood lipid levels, body mass 
index or height) can be analyzed by linear regression [49]. 
By  definition,  rare  variants  have  low  population 
frequency, and the statistical power to detect association 
with a phenotype is low for modestly sized studies. For 
example,  assuming  10%  disease  prevalence,  in  a  study 
with 1,000 cases and 1,000 controls, there is 2% power to 
detect  an  association  for  a  rare  variant  (minor  allele 
frequency of 0.5%), with a threefold effect at the genome-
wide significance level of 5 × 10-8.
Multiple variant tests
Groups  of  variants  can  be  analyzed  together  in  an 
attempt to improve power. In whole genome sequencing, 
a sliding window can be used to group variants, whereas 
in exome sequencing the natural unit of grouping is one 
gene.  Alternative  splicing  can  complicate  this  analysis, 
however,  as  a  single  variant  might  belong  to  multiple 
transcripts  of  the  same  gene  with  different  functional 
effects (a variant might be classified as synonymous for 
one transcript and missense for another, for example). To 
extend the single variant tests above, single-SNP P-values 
from multiple variants can be combined by Fisher’s [50] 
or Stouffer’s [51] methods. Variants can also be combined 
in multiple logistic or linear regression models. However, 
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are depicted. The horizontal bars indicate aligned exome sequences for individuals; stars indicate the presence of a non-reference allele. Variants 1 
and 4 represent low-frequency variants with predominance in cases, Variant 2 represents a singleton, Variant 3 represents a common variant, and 
Variant 5 represents a low-frequency variant exclusive to controls. For simplicity, these variants are displayed with similar frequency, although very 
rare variants represent the majority of variation in real sequencing studies. As illustrated, the specific genetic architecture underlying the complex 
phenotype of interest is expected to have a large role in which test is most powerful for detecting an association. Collapsing methods may be best 
if a burden of rare variants drives the phenotype, whereas aggregation methods may be more powerful if the full allelic spectrum is contributory. 
Finally, for genes harboring both risk and protective alleles, bidirectional tests may be most appropriate. See Additional file 1 for examples of 
methods of each type. MAF, minor allele frequency.
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variant  separately  and  then  combine  evidence  from 
multiple variants, the results must be adjusted for many 
degrees of freedom, which will limit the power of these 
approaches.
Given the large amount of human genetic variation, it 
would  not  be  surprising  to  find  neutral  variants  in  a 
causal gene. Therefore, selecting a subset of variants for 
regression  can  improve  the  power  to  detect  an 
association.  For  example,  synonymous  variants  are 
typically  discarded  because  they  are  less  likely  to  be 
causal. Shrinkage and regularization regression methods 
such as LASSO [52], ridge regression [53], and stepwise 
regression have been proposed for association studies. In 
these  methods,  the  regression  model  is  fitted  while 
accounting for the cost of adding each additional variable 
to the model. Other approaches, such as logic regression 
[54] and the method proposed by Han and Pan [55], use 
data-driven combinations of variants to select variables 
for regression.
Collapsing methods
Another  approach  to  increasing  power  is  to  collapse 
multiple  rare  variants  together  for  analysis.  The 
framework of these tests involves collapsing all variants 
across  a  unit  (each  gene  being  a  unit,  for  example) 
together so that even if variants are individually rare, they 
might be jointly present in sufficient frequency to be used 
in a univariate test. When used for dichotomous traits, 
collapsing  methods  test  whether  the  overall  burden  of 
rare  variants  is  higher  in  cases  than  controls.  For 
example,  CAST  [56]  examines  the  differences  in  the 
number  of  individuals  with  one  or  more  rare  variants 
between  cases  and  controls,  and  the  CMC  test  [57]  is 
based on comparison of non-synonymous rare variants 
between  cases  and  controls.  These  tests  rely  on 
designating a set of variants as ‘rare’ for inclusion, and it 
is not surprising that altering this definition can greatly 
influence the association results. Unfortunately there is 
little guidance in this area and allele frequency thresholds 
of 1% or 5% are commonly (and arbitrarily) chosen. An 
alternative  approach  has  been  developed  that  uses  the 
data to select the best variants. The variable-threshold 
test  [58]  finds  the  frequency  threshold  that  best 
discriminates cases from controls. Similarly, RareCover 
[59] aims to find the optimal set of variants to collapse 
together.  Although  there  have  been  no  published 
complex-disease  exome  sequencing  studies,  these  tests 
have been applied to candidate gene sequencing results 
[58,60].
Aggregation methods
An  alternative  to  the  collapsing  methods  involves 
aggregation, which aims to summarize the information 
from  many  variants  while  appropriately  weighing  the 
contribution  of  each  variant.  Although  collapsing 
methods discard variants that are considered unlikely to 
be causal, aggregation methods aim to include the full 
frequency  spectrum  of  alleles  (rare  and  common)  into 
the  association  test.  The  weighted-sum  statistic  [61] 
weighs  variants  according  to  allele  frequency  (rare 
variants  are  given  stronger  weighting)  because  of  an 
assumption  that  functional  variants  of  large  effect  are 
kept at a low population frequency by purifying selection. 
Weighing variants by apparent effect size is also effective 
and is implemented in KBAC [62] and the test described 
by Ionita-Laza et al. [63]. These tests have been applied to 
candidate gene sequencing results [58].
Extensions to these methods
Accounting for covariates
The  association  of  genotype  with  phenotype  can  be 
confounded by various factors such as ancestry, age and 
sex.  Methods  that  can  directly  account  for  such 
covariates can be advantageous in discerning the causal 
effect of genetic variants. When a test does not directly 
accommodate  covariates,  regressing  the  genotype  and 
phenotype on the covariate and using the residuals for 
the  association  analysis  can  remove  the  effect  of  the 
covariate on the phenotype.
Accounting for risk and protective alleles together
The effects of genetic variants can be neutral, protective 
or  detrimental  for  a  given  disease  trait.  Many  existing 
methods  test  for  a  frequency  differential  of  variants 
between cases and controls and a mixture of positive and 
negative  effects  will  adversely  affect  these  tests.  For 
example,  PCSK9  (encoding  proprotein  convertase 
subtilisin/kexin type 9), a gene associated with cholesterol 
levels  and  coronary  artery  disease,  contains  both  risk-
lowering  loss-of-function  variants  and  gain-of-function 
variants that increase risk [64]. Testing for a difference in 
the aggregate of these alleles in either cases or controls 
would not be expected to yield significant results as cases 
will  be  enriched  for  risk  variants  and  controls  will  be 
enriched  for  protective  variants,  effectively  canceling 
each other out in the sum total. Methods that account for 
a mixture of directions of effects can be more powerful in 
such  scenarios,  and  several  tests  explicitly  account  for 
bidirectionality  of  effects  (Additional  file  1).  The 
prevalence  of  genes  with  variants  having  bidirectional 
effects is currently unknown but loss-of-function variants 
are  expected  to  be  more  abundant  in  the  general 
population  and  this  bidirectional  effect  may  be  less 
apparent  for  sequencing  studies  not  focusing  on 
phenotypic extremes. Regardless, it is likely that multiple 
genes  in  a  common  pathway  would  have  alleles  with 
bidirectional effects, and if a collapsing method is used to 
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increasingly used.
Incorporating functional annotations
Several  studies  have  shown  that  using  functional 
information  improves  the  power  to  detect  association 
[58,65-67]. For protein-coding variants this can include 
the predicted effect on protein function, using programs 
such as SIFT [33,68], PolyPhen [32,69], Panther [70,71], 
MutationAssessor [72], SNAP [73] and PupaSuite [74]. 
For non-coding variants, evolutionary conservation and 
functional effects can be assessed using programs such as 
PhyloP [75], PhastCons [76], SCONE [77] and SiPhy [78].
Statistical power
The  statistical  power  of  the  methods  to  test  for 
association with rare variants has not been systematically 
analyzed. Although articles that describe novel associa-
tion tests usually provide power comparisons to previous 
methods, these calculations are prone to being performed 
under specific assumptions about the genetic architecture 
of the trait that often favors the test being implemented 
and  might  not  be  representative  for  human  traits  in 
general  [79,80].  Extending  the  results  from  theoretical 
studies  [81]  and  early  sequencing  studies  of  candidate 
genes [41,42,82] would suggest that approximately 10,000 
exomes are needed to achieve genome-wide significance 
for complex traits (in which a Bonferroni-corrected P-
value for 20,000 genes would require P < 2.5 × 10-6). Even 
the most powerful of the methods available for analyzing 
sequencing  data  will  not  lower  these  requirements 
substantially. It would not be surprising, then, that the 
first exome sequencing association studies will be under-
powered and exome sequencing will need to be replicated 
with additional sequencing or genotyping (or both) [83].
Which test(s) should be used?
The  decision  regarding  the  use  of  specific  tests  will 
depend on many factors, including study design (if the 
trait is quantitative or dichotomous), the assumption of 
the  underlying  genetics  (whether  only  rare  variants  or 
both  rare  and  common  variants  are  expected  to 
contribute  to  disease,  whether  protective  and  risk 
variants  are  expected),  and  pragmatic  considerations 
(which  test  is  available  for  use).  Most  importantly, 
different  tests  are  powered  to  detect  associations  for 
different  aspects  of  genetic  architectures  (number  of 
affected  loci,  associated  population  frequencies,  or 
associated  effect  sizes  and  directions)  [79,84,85]. 
Currently, no software suite contains more than a small 
number of tests and input formats vary between available 
software packages, which complicates applying multiple 
tests to the same study. In the future we expect multiple 
tests to be implemented in available software suites.
Challenges for exome sequencing applied to complex 
disease
Numerous  tests  have  been  developed  for  analyzing 
sequencing  data  (Additional  file  1).  Running  a  large 
battery  of  these  tests  comes  at  the  cost,  however,  of 
having to penalize multiple hypothesis testing, as well as 
potential confusion over inconsistent results (a gene can 
be  highly  ranked  in  one  test  and  not  significant  in 
another, for instance). Regardless of the test, unless rare 
variants  have  a  surprisingly  large  phenotypic  effect  on 
complex  diseases,  achieving  sufficient  statistical  power 
will  require  large  studies.  DNA  sequencing  costs  will 
continue  to  decrease,  however,  and  adequately  sized 
studies  might  soon  be  performed  (simulations  suggest 
that  5,000  cases  and  5,000  controls  would  provide 
adequate  power  to  detect  association  for  rare  variants 
with  modest  effect  [81]).  Combining  results  from 
different studies on the same phenotype is an attractive 
intermediate option (as has been seen with increasingly 
larger  GWAS  meta-analyses).  This  will  probably  prove 
more challenging than GWAS meta-analysis, however, as 
differences in results from multiple sequencing centers 
(perhaps  with  different  sequencing  technologies  or 
different  exome  target  definitions,  for  example)  can 
introduce  significant  technical  artifacts.  Once  putative 
variants have been discovered, the replication strategy for 
exome  studies  will  depend  on  the  genetic  architecture 
discovered  in  the  analysis.  Disease-associated  low-
frequency polymorphisms can be verified with follow-up 
genotyping. If the phenotype is caused by a collection of 
singleton  variants,  however,  further  sequencing  in 
additional  individuals  will  be  needed  and  might  prove 
expensive  (especially  if  multiple  genes  are  being 
considered or if genes are large or have many exons).
Prospects for the future
The  growing  number  of  exome  sequencing  studies 
demonstrates  the  power  of  this  approach  in  mapping 
genes involved in Mendelian phenotypes. The success of 
this approach is uncertain, however, as publication bias 
makes  it  unclear  how  many  studies  fail  to  identify  a 
causal  locus  by  exome  sequencing.  Non-allelic 
heterogeneity,  regulatory  variation  and  structural 
variation underlying phenotypes all pose challenges for 
sequencing-based  discovery  of  Mendelian  genes.  It  is 
possible that new statistical and computational methods 
will increase the already impressive success rate of exome 
sequencing studies for Mendelian disorders.
Although we are still awaiting the completion of the 
first  exome  sequencing  studies  focusing  on  complex 
phenotypes,  the  early  studies  will  probably  be  under-
powered because current sequencing costs prohibit the 
adequately  sized  samples  discussed  above  (10,000 
samples). Owing to this lack of power, the first studies 
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involved in traits of medical relevance. We believe that 
the  enthusiasm  for  sequencing  studies  should  not  be 
diminished, however, because this technology has already 
shown great promise in the field of Mendelian disorders 
and sequencing costs will continue to decline, leading to 
adequately  powered  studies  for  complex  traits.  Tech-
nology already allows for the complete characterization 
of genetic diversity. The success of complex trait genetic 
research  will  now  be  determined  by  our  ability  to 
interpret  the  data  and  assemble  sufficiently  large  well-
phenotyped clinical populations.
Additional materials
Additional file 1: A table of available statistical methods for 
analyzing variants discovered in sequencing studies.
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